Testosterone for Postmenopausal HSDD: Real Evidence, No FDA-Approved Product
The one androgen indication in women with real randomized evidence behind it — and no FDA-approved product in the U.S. to actually prescribe for it.
Beatrice L., a 56-year-old woman, retired two years ago from a long career as a hospital pharmacist and describes her marriage, five years past her own menopause, as otherwise close and unstrained — except for a loss of sexual desire that has become a real source of distress for her personally, not primarily a complaint from her husband. She's tried vaginal moisturizers for dryness with partial relief and has never been on systemic hormone therapy of any kind. She's read enough during her pharmacy career to ask specifically about testosterone, and to ask, pointedly, why it isn't simply prescribed the way estrogen is.
Her presentation matches, closely, the one population the actual evidence base for testosterone in women is built around. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis et al., JCEM), endorsed by ten international societies including the Endocrine Society and ISSWSH, found the only evidence-based indication for testosterone in women is HSDD in postmenopausal patients, with real, Level 1 Grade A trial evidence supporting a moderate benefit — roughly one additional satisfying sexual event per month, along with reduced sexual distress and improved desire, arousal, and pleasure. What the statement cannot resolve for her is access: despite that evidence base, the FDA has never approved a testosterone formulation for women, which means any prescription here means reaching for an off-label, dose-adjusted male product or a compounded preparation — neither of which is the carefully titrated, physiologic- dose formulation the underlying trials actually tested.
Beatrice brought a specific, informed question to the visit that her pharmacy background makes her unusually equipped to ask: whether the male-formulation products she'd read about being compounded down for women actually deliver a consistent physiologic dose, or whether the tenth-of-a-tube approach patients are sometimes told to use introduces real variability she should know about before committing to it. She said she wasn't looking for reassurance so much as an honest answer, having spent a career watching patients get exactly that kind of vague reassurance about medications she knew, professionally, deserved a more precise one. She also asked whether her own baseline testosterone level, drawn today and returned as low-normal, was itself diagnostic of anything, or simply confirmed what the visit already suspected without adding real decision-making weight either way.
Consult, the question already asked directly
Her presentation matches the one indication testosterone in women actually has real evidence for. The 2019 Global Consensus Statement, endorsed by ten international societies, found Level 1 Grade A evidence for testosterone specifically in postmenopausal HSDD — roughly one additional satisfying sexual event per month, reduced distress, improved desire and arousal. The lack of a US- approved product is a real practical problem, but it isn't a reason to withhold a therapy this well-supported from a patient it's specifically indicated for.
If she didn't carry real personal distress about it — if this were only her husband's complaint — I wouldn't be making this argument the same way; the diagnosis itself requires the distress to be hers.
I'd name the gap between the evidence and what's actually prescribable more directly before we go further. Essentially every trial behind the Global Consensus Statement used carefully titrated, physiologic-dose formulations manufactured specifically for that purpose — not an off-label male gel dosed down by a tenth, and not a compounded preparation with real batch-to-batch variability. The evidence is genuine; what's practically available to write a prescription for in the US isn't the same thing the trials tested.
I'm not arguing against testosterone as a legitimate option here — I'm arguing she deserves to understand that the formulation gap is real dosing uncertainty, not a bureaucratic footnote, before she commits to either approach.
Before either of those options, I'd want her untreated menopausal symptoms addressed first. Vaginal dryness and occasional vasomotor symptoms are both real, documented, and undertreated right now — and undertreated menopausal symptoms are themselves a well-recognized, distinct contributor to low desire, separate from any androgen-specific mechanism. Trying local vaginal estrogen and, if needed, systemic estrogen first is the simpler, already-approved step, and it may meaningfully change the picture before reaching for a harder-to-access drug.
Agreed: a three-month trial of estrogen therapy for her documented, untreated vaginal and vasomotor symptoms first, with testosterone named directly to Beatrice as the well-evidenced next step if her desire complaint doesn't meaningfully improve — including an honest account of the formulation gap between what the trials tested and what's actually available to prescribe in the US. She left the visit with both the evidence and the access problem named plainly, not smoothed into a single recommendation.